Drug Lawsuit Against Genentech (RHHBY) Could Burden Customers
6/24/2013 7:53:30 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
A legal spat that includes South San Francisco biotech giant Genentech has the potential to cost patients who need several drug treatments, including a handful for cancer treatment.
Citing derelict royalty payments on several drug treatments — including three for cancer — Nevada-based PDL BioPharma filed a notice of arbitration earlier this month against Genentech. The suit stems from a 2003 agreement that the two companies made over a patent dispute, which required Genentech to pay licensing fees to use PDL's medical technologies.
Genentech has oft been touted as a leader in cancer treatment, creating antibody drugs that strike tumors while causing minimal damage to surrounding tissue. Its sought-after drug Herceptin, which fights metastatic breast tumors, is one of the drugs affected by the suit.
Help employers find you! Check out all the jobs and post your resume.
comments powered by